Enterprise Value
-99.18M
Cash
226.4M
Avg Qtr Burn
-18.35M
Short % of Float
9.04%
Insider Ownership
16.17%
Institutional Own.
60.24%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KB-0742 (CDK9 Inhibitor) Details Solid tumor/s | Phase 1/2 Data readout | |
Lanraplenib (SYK Inhibitor) Details Blood cancer, Leukemia, Acute myeloid leukemia, Cancer | Phase 1/2 Data readout | |
Entospletinib (SYK Inhibitor) Details HOXA9/MEIS1-high AML (Acute myeloid leukemia) | Failed Discontinued |